Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, United Kingdom of Great Britain and Northern Ireland.
Life Sci. 2019 Oct 1;234:116776. doi: 10.1016/j.lfs.2019.116776. Epub 2019 Aug 16.
Glucagon-like peptide-1 is a peptide of incretin family which is used in the management of diabetes as glucagon-like peptide-1 receptor agonist (GLP-1RA). Dipeptidyl peptidase-4 enzyme metabolizes glucagon-like peptide-1 and various dipeptidyl peptidase-4 enzyme inhibitors (DPP-4i) are also used in the management of diabetes. These antidiabetic agents provide anti-hyperglycemic effects via several molecular mechanisms including promoting insulin secretion, suppression of glucagon secretion and slowing the gastric emptying. There is some research suggesting that they can induce insulin sensitivity in peripheral tissues. In this study, we review the possible molecular mechanisms by which GLP-1RA and DPP-4i can improve insulin resistance and increase insulin sensitivity in insulin-dependent peripheral tissues.
胰高血糖素样肽-1 是肠促胰岛素家族的一种肽，作为胰高血糖素样肽-1 受体激动剂 (GLP-1RA) 用于糖尿病的治疗。二肽基肽酶-4 酶代谢胰高血糖素样肽-1，各种二肽基肽酶-4 酶抑制剂 (DPP-4i) 也用于糖尿病的治疗。这些抗糖尿病药物通过多种分子机制提供抗高血糖作用，包括促进胰岛素分泌、抑制胰高血糖素分泌和减缓胃排空。有一些研究表明，它们可以诱导外周组织的胰岛素敏感性。在这项研究中，我们综述了 GLP-1RA 和 DPP-4i 改善胰岛素抵抗和增加胰岛素敏感性的可能分子机制。
